• Categories:Industry news
• Author:
• Origin:
• Time of issue:2018-09-28 23:30
• Views:

(Summary description)Recently, the Institute of Process Engineering, Chinese Academy of Sciences learned that a team led by Ma Guanghui, a researcher at the Institute, developed a recombinant human growth hormone sustained-release microcapsule with uniform particle size. The relevant results were published in the international academic journal Molecular Pharmacy. It is understood that recombinant human growth hormone (rhGH) is widely used in clinical treatment of short stature, severe burns, lipodystrophy in AIDS patients and other diseases. However, the half-life of rhGH is short, and frequent injections are required to achieve effective plasma concentrations, resulting in poor patient compliance. In response to this problem, scientists have conducted a lot of research on rhGH sustained-release microcapsules, but there are still common problems such as uneven particle size of microcapsules, unsustainable release, and poor drug stability. At the same time, the acidic products produced during the degradation of traditional hydrophobic material microcapsules can cause inflammation at the injection site and cause serious side effects. Therefore, the development of safe and effective rhGH sustained-release microcapsules has important research significance. This time, Ma Guanghui's team first used the W/O/W double emulsion method to load rhGH into the amphiphilic polylactic acid-polyethylene glycol copolymer emulsion, and combined with the rapid membrane emulsification technology to achieve the uniformity of the particle size of the microspheres . Subsequent in vivo rat model experiments show that the preparation can effectively prolong the release of rhGH in the body, and maintain the activity of rhGH well, and the rat bones grow significantly, which improves the therapeutic effect. In addition, compared with traditional polylactic acid (PLA) and polylactic acid-co-glycolic acid (PLGA) microcapsules, the preparation does not produce inflammatory reactions and has no effect on the functions of major organs such as the heart, liver, and kidneys. Safe sustained release carrier. The research work was supported by the "973" project and the National Natural Science Foundation of China.